Multiple Sclerosis (MS) is an immune mediated disease of the Central Nervous System. The heterogeneous manifestation and clinical course of MS are explained by several factors, among them the multi-factorial nature of the disease, where the interaction of genetic, lifestyle, and environmental factors confer the susceptibility. The altered balance between the effector and the regulatory arm of the immune system plays a crucial role in MS pathogenesis. However, although the number of immunomodulators able of restoring at least some of this unbalance, available for MS treatment, has expanded in the recent years, it remains an incurable disease. Even targeted therapy has failed to control disease progression.
There is, therefore, an urgent need to revise MS pathophysiology beyond immune-mediated inflammation. Besides the defined role of the adaptive immune system, several pieces of evidence support the participation of parallel pathophysiological mechanisms in MS pathogenesis, including hemostatic dysfunction (both primary, secondary and tertiary hemostasis), glial cell dysfunction (in particular oligodendrocytes), blood-brain barrier abnormalities, and metabolism alteration. These research fields have demonstrated substantial progress in the last years offering new potential biomarkers and therapeutic targets in MS. However, a great deal of effort is still needed for this evidence to impact clinical practice.
We welcome submissions of Original Research, Reviews, Perspectives and Opinions in the following areas:
• The role of hemostatic dysfunction, oligodendrocytes dysfunction, blood-brain barrier abnormalities and metabolism in the pathogenesis of MS.
• How the alteration of the hemostatic and metabolic pathways could serve as diagnostic, prognostic, or therapeutic biomarkers.
• How the alteration of the hemostatic and metabolic pathways could serve as potential therapeutic targets.
Topic Editor Luigi Lavorgna received AB and/or fee consultancy from: Roche, Biogen, Viatris, Bristol-Meyers, Novartis, Merck-Serono, Sanofi-Genzyme. Theother Topic Editors declare no competing interests with regards to the Research Topic subject.
Keywords:
Multiple Sclerosis, hemostasis, coagulation, oligodendrocytes, blood-brain barrier, metabolism
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
Multiple Sclerosis (MS) is an immune mediated disease of the Central Nervous System. The heterogeneous manifestation and clinical course of MS are explained by several factors, among them the multi-factorial nature of the disease, where the interaction of genetic, lifestyle, and environmental factors confer the susceptibility. The altered balance between the effector and the regulatory arm of the immune system plays a crucial role in MS pathogenesis. However, although the number of immunomodulators able of restoring at least some of this unbalance, available for MS treatment, has expanded in the recent years, it remains an incurable disease. Even targeted therapy has failed to control disease progression.
There is, therefore, an urgent need to revise MS pathophysiology beyond immune-mediated inflammation. Besides the defined role of the adaptive immune system, several pieces of evidence support the participation of parallel pathophysiological mechanisms in MS pathogenesis, including hemostatic dysfunction (both primary, secondary and tertiary hemostasis), glial cell dysfunction (in particular oligodendrocytes), blood-brain barrier abnormalities, and metabolism alteration. These research fields have demonstrated substantial progress in the last years offering new potential biomarkers and therapeutic targets in MS. However, a great deal of effort is still needed for this evidence to impact clinical practice.
We welcome submissions of Original Research, Reviews, Perspectives and Opinions in the following areas:
• The role of hemostatic dysfunction, oligodendrocytes dysfunction, blood-brain barrier abnormalities and metabolism in the pathogenesis of MS.
• How the alteration of the hemostatic and metabolic pathways could serve as diagnostic, prognostic, or therapeutic biomarkers.
• How the alteration of the hemostatic and metabolic pathways could serve as potential therapeutic targets.
Topic Editor Luigi Lavorgna received AB and/or fee consultancy from: Roche, Biogen, Viatris, Bristol-Meyers, Novartis, Merck-Serono, Sanofi-Genzyme. Theother Topic Editors declare no competing interests with regards to the Research Topic subject.
Keywords:
Multiple Sclerosis, hemostasis, coagulation, oligodendrocytes, blood-brain barrier, metabolism
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.